Health Trials

Imaging Study of a TROP2 Binder in Metastatic UC, HR+ and HER2- Breast Cancer, TNBC, and NSCLC

ConditionsMetastatic Urothelial CarcinomaBreast CancerTNBC - Triple-Negative Breast CancerHormone Receptor Positive HER-2 Negative Breast CancerNSCLC
Trial statusNot yet recruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorRayzeBio, Inc.

About this trial

This imaging study aims to assess the feasibility, biodistribution, and dosimetry of a TROP2 binder in subjects with metastatic UC, HR+ and HER2- breast cancer, TNBC, or NSCLC.

Eligibility criteria

Qualifiers

Are at least 18 years old at the time of signing the informed consent form (ICF)

Have biopsy proven metastatic UC, HR+ and HER2- breast cancer, TNBC, or NSCLC

Disqualifiers

TROP2-targeting antibody-drug conjugates (ADCs) such as sacituzumab govitecan or datopotamab deruxtecan, should be discontinued at least 90 days prior to administration of RYZ211 and RYZ212

For Women of Childbearing Potential: Are pregnant or breastfeeding

Trial design

Treatments tested in this trial

  • RYZ211/212

Treatment groups

40 Participants
are divided into 1 treatment group

Sponsors and collaborators

RayzeBio, Inc.

Lead sponsor

Source ClinicalTrials.gov